Your browser doesn't support javascript.
loading
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.
Boutsikos, Ioannis; Beltsios, Eleftherios; Schmack, Bastian; Pantazopoulos, Ioannis; Chatzis, Dimitrios G.
Afiliação
  • Boutsikos I; Department of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Beltsios E; Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Schmack B; Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Pantazopoulos I; Department of Emergency Medicine, Medical School, University of Thessaly, Larissa, Greece.
  • Chatzis DG; School of Medicine, European University of Cyprus, Nicosia, Cyprus.
Heart Int ; 17(2): 12-18, 2023.
Article em En | MEDLINE | ID: mdl-38419717
ABSTRACT
Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article